Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

The Almond Yogurt Study (AYS) (AYS)

maanantai 16. marraskuuta 2026 päivittänyt: Amanda Wright, Ph.D., University of Guelph

The Impact of Almond Food Structure in a Standardized Yogurt Breakfast Meal on Gastric Emptying, Oral Processing Behaviours, Appetite-Regulating Hormones, Postprandial Metabolism, and Subjective Satiety: A Randomized Crossover Trial

The goal of this clinical trial is to explore how almond food structure influences gastric emptying rates when consumed by healthy adult women as part of a standardized breakfast meal. The main questions it aims to answer are:

  • Does the structure of almonds (whole, chopped, buttered) influence gastric emptying ?
  • What is the correlation between chewing behaviour, gastric emptying, and changes in postprandial triacylglycerols and satiety (hormones and ratings) within the context of an increasingly disrupted nut matrix.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

This study is investigating how the structure of almonds (whole, chopped, buttered) as part of a yogurt-based breakfast meal influences gastric emptying and postprandial metabolism. Over three randomized visits, fasted healthy adult female participants will arrive at the research centre where an iv-catheter will be inserted for serial blood sampling over 6 hours for analysis of plasma triacylglycerols, GLP-1, CCK, glucose, and insulin. Participants will consume each meal while being video recorded to quantify chewing frequency and eating time. Paper questionnaires will periodically assess participants' eating experiences and hunger sensations throughout the visit (e.g., exertion, liking, hunger, fullness). Gastric ultrasonography will be used to visualize and quantify the cross-sectional area of the gastric antrum so that changes in gastric volume can be tracked over time. Overall, this study aims to determine how almond form, as an example of food structure, influences chewing, gastric emptying, satiety and postprandial metabolism.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

25

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Opiskelupaikat

    • Ontario
      • Guelph, Ontario, Kanada, N1G 2G4
        • Department of Human Health Sciences
        • Ottaa yhteyttä:
        • Ottaa yhteyttä:
          • Alison M Duncan, PhD
        • Päätutkija:
          • Amanda J Wright, PhD

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta - 45 vuotta (Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Joo

Sukupuolet, jotka voivat opiskella

Nainen

Kuvaus

Inclusion Criteria:

  • Healthy female adults aged 18-45 years.
  • Body Mass Index (BMI) between 18.5-27.9 kg/m2, or waist circumference of less than 88 cm
  • Visible gastric antrum on ultrasound
  • No known food allergies or sensitivities
  • Non restrained eaters (TFEQ, see below)
  • No history of gastrointestinal diseases that may interfere with eating behavior or digestion
  • Not on medications that affect appetite (including GLP-1 agonists), digestion, blood sugar regulation, saliva production, or chewing
  • Stable medication use
  • Non-smokers
  • Not gained or lost significant weight during the past 3 months
  • Regular monthly menstrual cycles
  • Not pregnant, lactating or post-menopausal

Exclusion Criteria:

  • Diabetes or other metabolic disorders affecting glycemia and overall cardiometabolic health
  • Blood pressure > 140/90 mm Hg
  • Any food allergies, intolerances, or sensitivities
  • Pregnant or breastfeeding
  • Participation in another clinical trial
  • Excessive alcohol consumption (more than 14 drinks per week)
  • Smokers or those with a smoking history of more than 10 years
  • Regular use of recreational drugs (e.g., marijuana, ecstasy, LSD, magic mushrooms, etc.)
  • Restrained eater (>16) as defined by the questionnaire at screening (Three-Factor Eating Questionnaire, Stunkard et al., 1985)
  • Unusual sleep patterns
  • Irregular breakfast consumption
  • Recent weight changes, or intended weight loss or gain; lost/gained 10% of body weight within the last 6 months
  • Food allergies/sensitivities or any life-threatening allergies
  • Using medications known to affect appetite, digestion, blood sugar regulation, or chewing/swallowing (excluding oral contraceptives).
  • Experiences dry mouth in general or due to medication side effects
  • Inability to adhere to study protocols
  • Not comfortable providing IV-line blood samples
  • Not comfortable providing ultrasound scans
  • Not comfortable being video recorded while eating
  • Avoids consuming almonds/yogurt in general
  • Avoids eating hard foods to prevent dental fractures

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Perustiede
  • Jako: Satunnaistettu
  • Inventiomalli: Crossover-tehtävä
  • Naamiointi: Kaksinkertainen

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Whole - Chopped - Buttered

Participants consume 115 g vanilla yogurt with 60 g whole almonds at the first intervention visit, chopped almonds at the second intervention visit, and almonds processed into almond butter at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Kokeellinen: Whole - Buttered - Chopped

Participants consume 115 g vanilla yogurt with 60 g whole almonds at the first intervention visit, buttered almonds at the second intervention visit, and chopped almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Kokeellinen: Buttered - Whole - Chopped

Participants consume 115 g vanilla yogurt with 60 g buttered almonds at the first intervention visit, whole almonds at the second intervention visit, and chopped almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Kokeellinen: Buttered - Chopped - Whole

Participants consume 115 g vanilla yogurt with 60 g buttered almonds at the first intervention visit, chopped almonds at the second intervention visit, and whole almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Kokeellinen: Chopped - Buttered - Whole

Participants consume 115 g vanilla yogurt with 60 g chopped almonds at the first intervention visit, buttered almonds at the second intervention visit, and whole almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Kokeellinen: Chopped - Whole - Buttered

Participants consume 115 g vanilla yogurt with 60 g chopped almonds at the first intervention visit, whole almonds at the second intervention visit, and buttered almonds at the third intervention visit.

Breakfast meal consisting of vanilla yogurt (115g) with almonds (60g) in different forms.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Gastric emptying half-time
Aikaikkuna: At each study visit, based on assessments at 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated from ultrasound imaging of the gastric antrum cross-sectional area at baseline (fasted) and after consumption of the breakfast meal, in minutes

At each study visit, based on assessments at 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Eating time
Aikaikkuna: From 0 minutes until the end of eating the breakfast meal

The time to consume the breakfast meal based on video recordings, in minutes

From 0 minutes until the end of eating the breakfast meal
Changes from baseline in postprandial satiety visual analogue scale ratings
Aikaikkuna: 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Paper questionnaire scale ratings (in mm) of Hunger, Fullness, Prospective Consumption, and Desire to Eat where each is 100 mm ranging from 0 (minimum) to 100 (maximum). For example, 0 = Not at all Hungry and 100 = As Hungry as Possible.

0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in plasma triacylglycerol concentration
Aikaikkuna: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in mmol/L

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Triacylglycerol response - incremental area under the curve (AUC)
Aikaikkuna: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in plasma GLP-1 concentration
Aikaikkuna: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in pg/mL

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
GLP-1 response - incremental area under the curve (AUC)
Aikaikkuna: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in plasma CCK concentration
Aikaikkuna: 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in pmol/L

0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
CCK response - incremental area under the curve (AUC)
Aikaikkuna: 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in gastric volume
Aikaikkuna: 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on ultrasound imaging of the gastric antrum cross-sectional area at baseline (fasted) and after eating the breakfast meal, in mL

0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Gastric volume - incremental area under the curve (AUC)
Aikaikkuna: 0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on ultrasound imaging of the gastric antrum cross-sectional area at baseline (fasted) and after eating the breakfast meal

0, 0.5, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Borg rating of perceived exertion
Aikaikkuna: Immediately after the breakfast meal is consumed

Participant paper scale rating of effort required to chew the breakfast meal where 0 = No effort at all and 10 = Very very severe chewing effort

Immediately after the breakfast meal is consumed
Changes from baseline in plasma blood glucose concentration
Aikaikkuna: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in mmol/mL

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Glucose response - incremental area under the curve (AUC)
Aikaikkuna: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Changes from baseline in plasma blood insulin concentration
Aikaikkuna: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Based on analysis of serial blood draws, in pmol/mL

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Insulin response - Area under the curve (AUC)
Aikaikkuna: 0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal

Calculated based on baseline and postprandial plasma concentrations

0, 1, 2, 3, 4, 5, & 6 hours from the start of eating the breakfast meal
Product liking and perceived attributes
Aikaikkuna: Immediately after eating the breakfast meal

Participant paper scale questionnaire ratings

Immediately after eating the breakfast meal
Eating rate
Aikaikkuna: From 0 minutes until the end of eating the breakfast meal

Calculated from video recordings of eating session, combining meal portion consumed (in grams) and eating time (minutes), grams/minute

From 0 minutes until the end of eating the breakfast meal
Number of chews
Aikaikkuna: From 0 minutes until the end of eating the breakfast meal

Determined by count from video recordings of each eating session

From 0 minutes until the end of eating the breakfast meal

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Sunnuntai 15. marraskuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Keskiviikko 15. joulukuuta 2027

Opintojen valmistuminen (Arvioitu)

Sunnuntai 19. joulukuuta 2027

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Torstai 29. lokakuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Maanantai 16. marraskuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Keskiviikko 18. marraskuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Keskiviikko 18. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 16. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

PÄÄTTÄMÄTÖN

IPD-suunnitelman kuvaus

Although we are not required to make this data available, we are currently working to understand how to do this in a safe way, as per our institutional guidelines. As we learn more, we may pursue this. We are obtaining consent from study participants for this option.

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa